Iambic Therapeutics, Inc.

EDGAR

Market value is not computed: no share count is recorded in its filings.

3 filing records in this dataset, filed from 2026-09-21 to 2026-11-16. Explore the available filing history and original sources.

Watchlist

Holdings and insider activity

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.

Window: transactions dated on or after 2025-11-18.

Open-market purchases (code P)
1 transactions, 718,750 shares
Sum of shares × price per share: 11,500,000
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

  • 2026-10-16 RASTETTER WILLIAM H C 192,579 —
  • 2026-10-16 RASTETTER WILLIAM H C 8,341 —
  • 2026-10-16 RASTETTER WILLIAM H C 76,801 0
  • 2026-10-16 RASTETTER WILLIAM H C 64,001 0
  • 2026-10-16 RASTETTER WILLIAM H C 36,805 0

5% holders (Schedule 13D and 13G)

  • Qatar Investment Authority 5.8% SCHEDULE 13G 10/15/2026

See all insider transactions

Registration statement

This company has filed to register securities with the SEC and has not yet filed an annual or quarterly report. Its financial statements are in the filing itself rather than structured data, so reported figures appear here once periodic reports are filed.

Offering terms · S-1 · 2026-09-21

Security
Common Stock, par value $0.001 per share
Maximum offering price
USD 100,000,000
Registration fee
USD 13,810 · 0.0138%

The maximum offering price is the amount the registration fee is computed on, not what the company expects to raise. The offering size and price range are in the prospectus.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

3 filings · 0 latest values · 0 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001997038, 1997038, IAM, edgar:1997038

Also known as Iambic Therapeutics, Inc.